🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

RecruitingPhase 4Ages 18 Years - anyAllKindai University
NCT05709626 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM) * STEMI patients * Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months Exclusion Criteria: * Patients taking anticoagulants * Patients under 18 years old * Patients with less than 1 year prognosis * Patients participating in other intervention studies
💊

What it tests

  • No aspirin (Prasugurel monotherapy)
  • 12-month DAPT
📍

Where

1 site
Kindai University Faculty of Medicine
Sayama, Japan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy